NASDAQ:PALI

Palisade Bio Q1 2025 Earnings Results & Report

Palisade Bio logo
$0.84 -0.09 (-9.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.02 (+2.39%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio beat analyst earnings expectations in its Q1 2025 results, released May 12, 2025. The company reported EPS of -$0.47 versus the -$0.84 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
6:00 PM ET

Palisade Bio EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.84
Beat/Miss
Beat by +$0.37
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Palisade Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Palisade Bio Q1 2025 Earnings FAQ

Palisade Bio (NASDAQ:PALI) reported earnings of -$0.47 per share for Q1 2025, beating the consensus estimate of -$0.84. The report was announced on Monday, May 12, 2025.

Palisade Bio Earnings Headlines

FY2026 EPS Estimate for Palisade Bio Reduced by Analyst
FY2026 EPS Forecast for Palisade Bio Reduced by Analyst
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More Palisade Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email.

About Palisade Bio

Palisade Bio (NASDAQ:PALI) is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions.

Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Palisade Bio’s candidates are in clinical development and are not approved for commercial use.

View Palisade Bio Profile